The use of PFKFB3 inhibitors has synergistic effects with chemotherapeutic and radiotherapeutic modalities via mitigation of TMR, promoting anti-tumor cytotoxicity, prolonging TVN, and modulating immune suppressive cells. The gene discussed is PFKFB3; the disease is neoplasm.